CTX101 Trademark

Trademark Overview

On Wednesday, April 11, 2018, a trademark application was filed for CTX101 with the United States Patent and Trademark Office. The USPTO has given the CTX101 trademark a serial number of 87872157. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 10, 2022. This trademark is owned by CRISPR Therapeutics AG. The CTX101 trademark is filed in the Pharmaceutical Products category with the following description:

Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; pharmaceutical products and preparations, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer
ctx101

General Information

Serial Number87872157
Word MarkCTX101
Filing DateWednesday, April 11, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 10, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 9, 2019

Trademark Statements

Goods and ServicesCells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; pharmaceutical products and preparations, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, February 2, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCRISPR Therapeutics AG
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
AddressZUG V8 6300
CH
Party NameCRISPR Therapeutics AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressBasel 4051
CH

Trademark Events

Event DateEvent Description
Monday, January 10, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 10, 2022ABANDONMENT - NO USE STATEMENT FILED
Friday, April 16, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 14, 2021SOU EXTENSION 4 GRANTED
Wednesday, April 14, 2021SOU EXTENSION 4 FILED
Wednesday, April 14, 2021TEAS EXTENSION RECEIVED
Wednesday, April 7, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, April 7, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, April 7, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, November 13, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 11, 2020SOU EXTENSION 3 GRANTED
Wednesday, November 11, 2020SOU EXTENSION 3 FILED
Wednesday, November 11, 2020TEAS EXTENSION RECEIVED
Wednesday, August 5, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 5, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, August 5, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 5, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, June 3, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 1, 2020SOU EXTENSION 2 GRANTED
Monday, June 1, 2020SOU EXTENSION 2 FILED
Monday, June 1, 2020TEAS EXTENSION RECEIVED
Friday, December 6, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 4, 2019SOU EXTENSION 1 GRANTED
Wednesday, December 4, 2019SOU EXTENSION 1 FILED
Wednesday, December 4, 2019TEAS EXTENSION RECEIVED
Tuesday, June 4, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, April 26, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, April 26, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, April 9, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 9, 2019PUBLISHED FOR OPPOSITION
Wednesday, March 20, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 1, 2019ASSIGNED TO LIE
Tuesday, February 12, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, February 2, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, February 1, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 1, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, August 7, 2018NOTIFICATION OF PRIORITY ACTION E-MAILED
Tuesday, August 7, 2018PRIORITY ACTION E-MAILED
Tuesday, August 7, 2018PRIORITY ACTION WRITTEN
Tuesday, July 31, 2018ASSIGNED TO EXAMINER
Thursday, April 19, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM

Related Keywords

treatment cancer pharmaceutical transfer gene modulation pharmaceuticals delivery namely regulation